A new approach to support specialist prescribing of bDMARDs
Arthritis Australia is part of an eight-member Consortium led by NPS MedicineWise, which is the successful recipient of the ‘Value in Prescribing biological disease-modifying anti-rheumatic drugs (bDMARDs)’ government grant.
The grant will fund a project to improve the use of bDMARDs to ensure the best health and economic outcomes from investment in these therapies.
NPS MedicineWise media release – bDMARDS September 2019 (002)
Discover more...
-
Millennials Face A Painful & Stiff Future || New Report Reveals Generations Hit Hardest with Arthritis
New forecast projections released today by Arthritis Australia reveal Millennials are facing a painful and debilitating health crisis by 2040, set to become a demographic...
-
Senator Tammy Tyrrell advocates for people living with fibromyalgia in parliament
February 7, 2024 || Senator Tyrrell advocates for people living with Fibromyalgia at the first parliamentary sitting week for 2024. “Almost one million Australians, including...
-
Anticipated Shortage of Abatacept (Orencia®)
Bristol Myers Squibb (BMS), the manufacturer of abatacept (Orencia®), has recently announced an expected shortage of both the ClickJect (autoinjector) and pre-filled syringe subcutaneous formulations...
Sign up to Arthritis Insights
Regular updates, news and research findings delivered to your inbox: